BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1446 related articles for article (PubMed ID: 9406705)

  • 21. The optimal fraction size in high-dose-rate brachytherapy: dependency on tissue repair kinetics and low-dose rate.
    Sminia P; Schneider CJ; Fowler JF
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):844-9. PubMed ID: 11849810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
    Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
    J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of 131I- and 90Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts.
    Buchsbaum DJ; Lawrence TS; Roberson PL; Heidorn DB; Ten Haken RK; Steplewski Z
    Int J Radiat Oncol Biol Phys; 1993 Mar; 25(4):629-38. PubMed ID: 8454481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radioimmunotherapy of human head and neck squamous cell carcinoma xenografts with 131I-labelled monoclonal antibody E48 IgG.
    Gerretsen M; Schrijvers AH; van Walsum M; Braakhuis BJ; Quak JJ; Meijer CJ; Snow GB; van Dongen GA
    Br J Cancer; 1992 Sep; 66(3):496-502. PubMed ID: 1520586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
    Ma D; McDevitt MR; Barendswaard E; Lai L; Curcio MJ; Pellegrini V; Brechbiel MW; Scheinberg DA
    Leukemia; 2002 Jan; 16(1):60-6. PubMed ID: 11840264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
    Bäck T; Andersson H; Divgi CR; Hultborn R; Jensen H; Lindegren S; Palm S; Jacobsson L
    J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of Efficacy of Radioimmunotherapy with 90Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models.
    Sugyo A; Tsuji AB; Sudo H; Okada M; Koizumi M; Satoh H; Kurosawa G; Kurosawa Y; Saga T
    PLoS One; 2015; 10(4):e0123761. PubMed ID: 25893775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intralesional radioimmunotherapy with Yttrium-90-labeled human monoclonal IgM in nude mice bearing human tumor xenografts.
    Borchardt PE; Vriesendorp HM; Freedman RS; Quadri SM
    Cancer Biother Radiopharm; 2004 Feb; 19(1):43-51. PubMed ID: 15068610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The irradiation tolerance dose of the proximal vagina.
    Au SP; Grigsby PW
    Radiother Oncol; 2003 Apr; 67(1):77-85. PubMed ID: 12758243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Timing effects of combined radioimmunotherapy and radiotherapy on a human solid tumor in nude mice.
    Sun LQ; Vogel CA; Mirimanoff RO; Coucke P; Slosman DO; Mach JP; Buchegger F
    Cancer Res; 1997 Apr; 57(7):1312-9. PubMed ID: 9102219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of 131I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts.
    Buchsbaum DJ; ten Haken RK; Heidorn DB; Lawrence TS; Glatfelter AA; Terry VH; Guilbault DM; Steplewski Z; Lichter AS
    Int J Radiat Oncol Biol Phys; 1990 May; 18(5):1033-41. PubMed ID: 2347713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 131I radioimmunotherapy and fractionated external beam radiotherapy: comparative effectiveness in a human tumor xenograft.
    Barendswaard EC; O'Donoghue JA; Larson SM; Tschmelitsch J; Welt S; Finn RD; Humm JL
    J Nucl Med; 1999 Oct; 40(10):1764-8. PubMed ID: 10520720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
    Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
    Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of brachytherapy practice for patients with carcinoma of the cervix (1996-1999): a patterns of care study.
    Erickson B; Eifel P; Moughan J; Rownd J; Iarocci T; Owen J
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1083-92. PubMed ID: 16099599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application of the cross-organ beta dose method for tissue dosimetry in tumor-bearing mice treated with a 90Y-labeled immunoconjugate.
    Beatty BG; Kuhn JA; Hui TE; Fisher DR; Williams LE; Beatty JD
    Cancer; 1994 Feb; 73(3 Suppl):958-65. PubMed ID: 8306285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined radioimmunotherapy and radiotherapy of human colon carcinoma grafted in nude mice.
    Buchegger F; Rojas A; Delaloye AB; Vogel CA; Mirimanoff RO; Coucke P; Sun LQ; Raimondi S; Denekamp J; Pèlgrin A
    Cancer Res; 1995 Jan; 55(1):83-9. PubMed ID: 7805046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
    Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
    Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A quantitative study of radionuclide characteristics for radioimmunotherapy from 3D reconstructions using serial autoradiography.
    Muthuswamy MS; Roberson PL; Ten Haken RK; Buchsbaum DJ
    Int J Radiat Oncol Biol Phys; 1996 Apr; 35(1):165-72. PubMed ID: 8641915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.
    Hartmann F; Horak EM; Garmestani K; Wu C; Brechbiel MW; Kozak RW; Tso J; Kosteiny SA; Gansow OA; Nelson DL
    Cancer Res; 1994 Aug; 54(16):4362-70. PubMed ID: 8044783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6.
    O'Donnell RT; DeNardo SJ; Miers LA; Lamborn KR; Kukis DL; DeNardo GL; Meyers FJ
    Prostate; 2002 Jan; 50(1):27-37. PubMed ID: 11757033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 73.